返回
Adagene Inc（ADAG）价格
ADAG 股价走势图
ADAG 收益
Adagene Inc
$1.96
2.08%
$0.04
收盘价：Jan 16, 16:00:00 GMT-5
$1.98
1.24%
$0.02
盘后：Jan 16, 20:00:00 GMT-5
关键数据
前收盘价
$1.92
开盘价
$1.88
当日区间
$1.88 - $1.98
52周范围
$1.3 - $3.16
交易量
53.8K
平均成交量
119.9K
每股收益（TTM）
-0.51
股息收益率
--
市值
$93.4M
什么是 ADAG？
Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu and currently employs 138 full-time employees. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.